Overview

Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration.

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
0
Participant gender:
All
Summary
Study to investigate if the uptake of Ticagrelor into the body differs depending on method of administration.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
AstraZeneca
Treatments:
Adenosine
Ticagrelor
Criteria
Inclusion Criteria:

- Healthy male and female volunteers aged 18 to 50 years (inclusive) with suitable veins
for cannulation or repeated venepuncture

- Have a body mass index between 18 and 30 kg/m2 (inclusive) and weigh at least 50 kg
(110 pounds [lbs]) and no more than 100 kg (220 lbs).

- Provision of signed and dated, written informed consent prior to any study specific
procedures

Exclusion Criteria:

- History of any clinically significant disease or disorder which, in the opinion of the
Investigator, may either put the volunteer at risk because of participation in the
study, or influence the results or the volunteer's ability to participate in the study

- History of haemophilia, von Willebrand's disease, lupus anticoagulant or other
diseases/syndromes that can either alter or increase the propensity for bleeding

- A personal history of vascular abnormalities including aneurysms; a personal history
of severe haemorrhage, haematemesis, melena, haemoptysis, severe epistaxis, severe
thrombocytopenia, intracranial haemorrhage; or rectal bleeding within 3 months prior
to the screeening visit; or history suggestive of peptic ulcer disease

- History of frequent and/or significant nose bleed or clinically significant non
traumatic bleed, bruise/haematoma or any other clinically significant bleeding risk,
as judged by the Investigator